Alfacell cancer news

Alfacell will restructure and reduce headcount by an undisclosed number. The move follows an FDA recommendation for an additional Phase III trial of the company's lead compound, Onconase ranpirnase, to treat unresectable malignant mesothelioma. The company said it does not have the financial resources to conduct the trial and instead will seek financing and strategic alternatives. In 2008, Alfacell reported the cytotoxic ribonuclease (RNase) missed the primary endpoint of survival versus doxorubicin in a Phase IIIb study, but it did show a survival benefit in a subset of patients who failed one prior chemotherapy regimen. ...